ArticleJCO oncology practice2021
Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
Article in JCO oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Are There Socio-Demographic Inequalities in the Utilisation of Tumour and ctDNA Somatic Mutation Testing in Solid Tumours? A Systematic Review.Cancer medicine · 2026Pooled it
- Genomic Testing Uptake Among Medicare Beneficiaries With Cancer.JAMA network open · 2026Article
- The 2023 clinical laboratory genetics workforce in the United States: trends, challenges, and evolving practices.Human genetics · 2026Article
- The role of circulating tumor DNA in ovarian cancer.Discover oncology · 2026Review
- Review
- Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing.JCO oncology practice · 2026Article
- A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling.Journal of the National Comprehensive Cancer Network : JNCCN · 2026Article
- Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies.JCO precision oncology · 2026Article
- Observational
- Article
- Current Status of Precision Medicine in Colorectal Cancer in Japan.International journal of molecular sciences · 2025Review
- Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare.JAMA network open · 2025Article
- Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY.JTO clinical and research reports · 2025Article
- Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting.Journal of the National Cancer Institute · 2025Article
- Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case report.Frontiers in oncology · 2025Article
- Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.Cancer research communications · 2024Article
- Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine.JCO precision oncology · 2024Review
- Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.JCO precision oncology · 2024Article
- Exploring the Genomic Landscape of Hepatobiliary Cancers to Establish a Novel Molecular Classification System.Cancers · 2024Article
- Benchmarking splice variant prediction algorithms using massively parallel splicing assays.Genome biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeIn 2018, Medicare issued a national coverage determination (NCD) providing reimbursement for next-generation sequencing (NGS) tests for beneficiaries with advanced or metastatic cancer and no previous NGS testing. We examined the association between NCD implementation and NGS utilization trends in Medicare beneficiaries versus commercially insured patients.
methodsThis was a retrospective study of patients with advanced non-small-cell lung cancer (aNSCLC), metastatic colorectal cancer (mCRC), metastatic breast cancer (mBC), or advanced melanoma with a de novo or recurrent advanced diagnosis from January 1, 2011, through December 30, 2019, using a nationwide US electronic health record-derived deidentified database. Patients were classified by insurance and by advanced diagnosis date. NGS testing was assessed by receipt of first NGS test result ≤ 60 days of advanced diagnosis. Interrupted time series analysis assessed NGS utilization pre- and post-NCD effective date by insurance type.
resultsThe utilization and repeat NGS testing analysis included 70,290 and 4,295 patients, respectively. Use of NGS rose from < 1% in 2011 to > 45% in Q4 2019 in aNSCLC while remaining < 20% in mBC and advanced melanoma. Among patients with aNSCLC, mCRC, or mBC, NGS testing increased post-NCD versus pre-NCD (
conclusionTrends in NGS utilization significantly changed post-NCD, although the magnitude of change was not significantly different by insurance type, indicating private insurers may also be incorporating NCD guidance. Implementation of the NCD may have limited use of repeat NGS testing in Medicare beneficiaries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.